Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 111 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MEYNARD G, Mansi L, Lebahar P, Villanueva C, et al
    First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
    Oncol Rep. 2017;37:1573-1578.
    PubMed     Text format     Abstract available


  2. XU H, Qian M, Zhao B, Wu C, et al
    Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells.
    Oncol Rep. 2017;37:1619-1626.
    PubMed     Text format     Abstract available


    February 2017
  3. GRIFFITH J, Andrade D, Mehta M, Berry W, et al
    Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
    Oncol Rep. 2017 Feb 28. doi: 10.3892/or.2017.5478.
    PubMed     Text format     Abstract available


  4. HUTH HW, Santos DM, Gravina HD, Resende JM, et al
    Upregulation of p38 pathway accelerates proliferation and migration of MDA-MB-231 breast cancer cells.
    Oncol Rep. 2017 Feb 14. doi: 10.3892/or.2017.5452.
    PubMed     Text format     Abstract available


  5. LUO P, Lu G, Fan LL, Zhong X, et al
    Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer.
    Oncol Rep. 2017 Feb 14. doi: 10.3892/or.2017.5449.
    PubMed     Text format     Abstract available


  6. ZHONG ZF, Tan W, Tian K, Yu H, et al
    Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro.
    Oncol Rep. 2017 Feb 10. doi: 10.3892/or.2017.5435.
    PubMed     Text format     Abstract available


  7. WU CW, Liu HC, Yu YL, Hung YT, et al
    Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways.
    Oncol Rep. 2017 Feb 10. doi: 10.3892/or.2017.5439.
    PubMed     Text format     Abstract available


    January 2017
  8. CAI S, Sun PH, Resaul J, Shi L, et al
    Expression of phospholipase C isozymes in human breast cancer and their clinical significance.
    Oncol Rep. 2017 Jan 20. doi: 10.3892/or.2017.5394.
    PubMed     Text format     Abstract available


  9. WANG N, Wei L, Huang Y, Wu Y, et al
    miR520c blocks EMT progression of human breast cancer cells by repressing STAT3.
    Oncol Rep. 2017 Jan 19. doi: 10.3892/or.2017.5393.
    PubMed     Text format     Abstract available


  10. YANG Z, Liu Y, Shi C, Zhang Y, et al
    Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways.
    Oncol Rep. 2017 Jan 9. doi: 10.3892/or.2017.5358.
    PubMed     Text format     Abstract available


  11. FU H, Fu L, Xie C, Zuo WS, et al
    miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.
    Oncol Rep. 2017 Jan 9. doi: 10.3892/or.2017.5360.
    PubMed     Text format     Abstract available


  12. CUI T, Zhang S, Sun H
    Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
    Oncol Rep. 2017 Jan 2. doi: 10.3892/or.2017.5345.
    PubMed     Text format     Abstract available


    December 2016
  13. WANG K, Sun X, Feng HL, Fei C, et al
    DNALK2 inhibits the proliferation and invasiveness of breast cancer MDA-MB-231 cells through the Smad-dependent pathway.
    Oncol Rep. 2016 Dec 30. doi: 10.3892/or.2016.5343.
    PubMed     Text format     Abstract available


  14. MENG C, Song L, Wang J, Li D, et al
    Propofol induces proliferation partially via downregulation of p53 protein and promotes migration via activation of the Nrf2 pathway in human breast cancer cell line MDA-MB-231.
    Oncol Rep. 2016 Dec 23. doi: 10.3892/or.2016.5332.
    PubMed     Text format     Abstract available


    November 2016
  15. LOU C, Zhu Z, Zhao Y, Zhu R, et al
    Arctigenin, a lignan from Arctium lappa L., inhibits metastasis of human breast cancer cells through the downregulation of MMP-2/-9 and heparanase in MDA-MB-231 cells.
    Oncol Rep. 2016 Nov 23. doi: 10.3892/or.2016.5269.
    PubMed     Text format     Abstract available


  16. LIU F, Zhang H, Song H
    Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
    Oncol Rep. 2016 Nov 18. doi: 10.3892/or.2016.5256.
    PubMed     Text format     Abstract available


  17. ZHOU T, Li Y, Yang L, Liu L, et al
    Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells.
    Oncol Rep. 2016 Nov 16. doi: 10.3892/or.2016.5251.
    PubMed     Text format     Abstract available


  18. XU X, Yan Q, Wang Y, Dong X, et al
    NTN4 is associated with breast cancer metastasis via regulation of EMT-related biomarkers.
    Oncol Rep. 2016 Nov 9. doi: 10.3892/or.2016.5239.
    PubMed     Text format     Abstract available


  19. JANG IS, Park JW, Jo EB, Cho CK, et al
    Growth inhibitory and apoptosis-inducing effects of allergen-free Rhus verniciflua Stokes extract on A549 human lung cancer cells.
    Oncol Rep. 2016;36:3037-3043.
    PubMed     Text format     Abstract available


  20. RATAJCZAK-WIELGOMAS K, Grzegrzolka J, Piotrowska A, Gomulkiewicz A, et al
    Periostin expression in cancer-associated fibroblasts of invasive ductal breast carcinoma.
    Oncol Rep. 2016;36:2745-2754.
    PubMed     Text format     Abstract available


  21. ARMANDO RG, Gomez DM, Gomez DE
    AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model.
    Oncol Rep. 2016;36:2731-2736.
    PubMed     Text format     Abstract available


  22. IIZUKA A, Kondou R, Nonomura C, Ashizawa T, et al
    Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
    Oncol Rep. 2016;36:2625-2632.
    PubMed     Text format     Abstract available


    October 2016
  23. LI M, Xiao D, Zhang J, Qu H, et al
    Expression of LPA2 is associated with poor prognosis in human breast cancer and regulates HIF-1alpha expression and breast cancer cell growth.
    Oncol Rep. 2016 Oct 26. doi: 10.3892/or.2016.5206.
    PubMed     Text format     Abstract available


  24. ZHAO W, Zhang X, Liu J, Sun B, et al
    miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7.
    Oncol Rep. 2016 Oct 24. doi: 10.3892/or.2016.5199.
    PubMed     Text format     Abstract available


  25. ZHANG Z, Liu L, Liu C, Cao S, et al
    TIPE2 suppresses the tumorigenesis, growth and metastasis of breast cancer via inhibition of the AKT and p38 signaling pathways.
    Oncol Rep. 2016 Oct 21. doi: 10.3892/or.2016.5192.
    PubMed     Text format     Abstract available


  26. CHEN X, Li Q, Kan XX, Wang YJ, et al
    Extract of Caulis Spatholobi, a novel blocker targeting tumor cellinduced platelet aggregation, inhibits breast cancer metastasis.
    Oncol Rep. 2016 Oct 19. doi: 10.3892/or.2016.5184.
    PubMed     Text format     Abstract available


  27. CUI HX, Wang H, Wang Y, Song J, et al
    ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules.
    Oncol Rep. 2016 Oct 18. doi: 10.3892/or.2016.5180.
    PubMed     Text format     Abstract available


  28. DU S, Li H, Sun X, Li D, et al
    MicroRNA-124 inhibits cell proliferation and migration by regulating SNAI2 in breast cancer.
    Oncol Rep. 2016 Oct 11. doi: 10.3892/or.2016.5163.
    PubMed     Text format     Abstract available


  29. BORDINHAO AL, Evangelista AF, Oliveira RJ, Macedo T, et al
    MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
    Oncol Rep. 2016 Oct 7. doi: 10.3892/or.2016.5153.
    PubMed     Text format     Abstract available


  30. ZHU C, Qi X, Zhou X, Nie X, et al
    Sulfatase 2 facilitates lymphangiogenesis in breast cancer by regulating VEGF-D.
    Oncol Rep. 2016 Oct 4. doi: 10.3892/or.2016.5143.
    PubMed     Text format     Abstract available


    September 2016
  31. XUE D, Liang Y, Duan S, He J, et al
    Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing alpha-Gal epitopes.
    Oncol Rep. 2016 Sep 23. doi: 10.3892/or.2016.5128.
    PubMed     Text format     Abstract available


  32. YAN F, Wang X, Zhu M, Hu X, et al
    RNAi-mediated downregulation of cyclin Y to attenuate human breast cancer cell growth.
    Oncol Rep. 2016 Sep 23. doi: 10.3892/or.2016.5126.
    PubMed     Text format     Abstract available


  33. YANG B, Zhao Y, Lou C, Zhao H, et al
    Eupalinolide O, a novel sesquiterpene lactone from Eupatorium lindleyanum DC., induces cell cycle arrest and apoptosis in human MDA-MB-468 breast cancer cells.
    Oncol Rep. 2016 Sep 21. doi: 10.3892/or.2016.5115.
    PubMed     Text format     Abstract available


  34. ZHANG L, Chen Z, Xue D, Zhang Q, et al
    Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker.
    Oncol Rep. 2016 Sep 20. doi: 10.3892/or.2016.5112.
    PubMed     Text format     Abstract available


  35. WEI YC, Zhang B, Li X, Liu XM, et al
    Upregulation and activation of deltaopioid receptors promotes the progression of human breast cancer.
    Oncol Rep. 2016 Sep 19. doi: 10.3892/or.2016.5109.
    PubMed     Text format     Abstract available


  36. OSANAI M, Lee GH
    CYP24A1-induced vitamin D insufficiency promotes breast cancer growth.
    Oncol Rep. 2016 Sep 5. doi: 10.3892/or.2016.5072.
    PubMed     Text format     Abstract available


  37. MA T, Yang L, Zhang J
    GPRC5A exerts its tumor-suppressive effects in breast cancer cells by inhibiting EGFR and its downstream pathway.
    Oncol Rep. 2016 Sep 2. doi: 10.3892/or.2016.5062.
    PubMed     Text format     Abstract available


    August 2016
  38. XU L, Peng S, Huang Q, Liu Y, et al
    Expression status of cyclaseassociated protein 2 as a prognostic marker for human breast cancer.
    Oncol Rep. 2016 Aug 25. doi: 10.3892/or.2016.5051.
    PubMed     Text format     Abstract available


  39. WANG Z, Jin J, Zhang J, Wang L, et al
    Depletion of SENP1 suppresses the proliferation and invasion of triple-negative breast cancer cells.
    Oncol Rep. 2016 Aug 24. doi: 10.3892/or.2016.5036.
    PubMed     Text format     Abstract available


  40. JI Y, Han Z, Shao L, Zhao Y, et al
    Ultrasound-targeted microbubble destruction of calcium channel subunit alpha 1D siRNA inhibits breast cancer via G protein-coupled receptor 30.
    Oncol Rep. 2016 Aug 23. doi: 10.3892/or.2016.5031.
    PubMed     Text format     Abstract available


  41. MATSUI S, Kagara N, Mishima C, Naoi Y, et al
    Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients.
    Oncol Rep. 2016 Aug 4. doi: 10.3892/or.2016.5004.
    PubMed     Text format     Abstract available


    July 2016
  42. HAN J, Jeon M, Shin I, Kim S, et al
    Elevated STC1 augments the invasiveness of triplenegative breast cancer cells through activation of the JNK/cJun signaling pathway.
    Oncol Rep. 2016 Jul 26. doi: 10.3892/or.2016.4977.
    PubMed     Text format     Abstract available


  43. JEON M, Han J, Nam SJ, Lee JE, et al
    STC-1 expression is upregulated through an Akt/NF-kappaB-dependent pathway in triple-negative breast cancer cells.
    Oncol Rep. 2016 Jul 25. doi: 10.3892/or.2016.4972.
    PubMed     Text format     Abstract available


  44. SUN J, Zhang X, Han Y, Zhen J, et al
    Overexpression of seven in absentia homolog 2 protein in human breast cancer tissues is associated with the promotion of tumor cell malignant behavior in in vitro.
    Oncol Rep. 2016 Jul 25. doi: 10.3892/or.2016.4976.
    PubMed     Text format     Abstract available


  45. FU OY, Chang HW, Lin YD, Chuang LY, et al
    Breast cancer-associated high-order SNP-SNP interaction of CXCL12/CXCR4-related genes by an improved multifactor dimensionality reduction (MDR-ER).
    Oncol Rep. 2016 Jul 21. doi: 10.3892/or.2016.4956.
    PubMed     Text format     Abstract available


  46. WANG J, Cui L, Feng L, Zhang Z, et al
    Isoalantolactone inhibits the migration and invasion of human breast cancer MDA-MB-231 cells via suppression of the p38 MAPK/NF-kappaB signaling pathway.
    Oncol Rep. 2016 Jul 20. doi: 10.3892/or.2016.4954.
    PubMed     Text format     Abstract available


  47. CHEN J, Wang F, Xu J, He Z, et al
    The role of PAQR3 gene promoter hypermethylation in breast cancer and prognosis.
    Oncol Rep. 2016 Jul 19. doi: 10.3892/or.2016.4951.
    PubMed     Text format     Abstract available


  48. KONG Y, Lu ZL, Wang JJ, Zhou R, et al
    Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
    Oncol Rep. 2016 Jul 13. doi: 10.3892/or.2016.4935.
    PubMed     Text format     Abstract available


  49. GOMES BC, Martins M, Lopes P, Morujao I, et al
    Prognostic value of microRNA-203a expression in breast cancer.
    Oncol Rep. 2016 Jul 5. doi: 10.3892/or.2016.4913.
    PubMed     Text format     Abstract available


    June 2016
  50. PISTELLI M, Ballatore Z, Santinelli A, Biscotti T, et al
    Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer.
    Oncol Rep. 2016 Jun 22. doi: 10.3892/or.2016.4903.
    PubMed     Text format     Abstract available


  51. XIE YG, Yu Y, Hou LK, Wang X, et al
    FYN promotes breast cancer progression through epithelial-mesenchymal transition.
    Oncol Rep. 2016 Jun 22. doi: 10.3892/or.2016.4894.
    PubMed     Text format     Abstract available


  52. ZHAO L, Feng X, Song X, Zhou H, et al
    miR-493-5p attenuates the invasiveness and tumorigenicity in human breast cancer by targeting FUT4.
    Oncol Rep. 2016 Jun 16. doi: 10.3892/or.2016.4882.
    PubMed     Text format     Abstract available


  53. GUO L, Zheng J, Zhang J, Wang H, et al
    Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression.
    Oncol Rep. 2016 Jun 15. doi: 10.3892/or.2016.4875.
    PubMed     Text format     Abstract available


  54. MAYNADIER M, Basile I, Gallud A, Gary-Bobo M, et al
    Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
    Oncol Rep. 2016 Jun 14. doi: 10.3892/or.2016.4873.
    PubMed     Text format     Abstract available


  55. LI M, Cai H, Yang Y, Zhang J, et al
    Perichondrium mesenchymal stem cells inhibit the growth of breast cancer cells via the DKK-1/Wnt/beta-catenin signaling pathway.
    Oncol Rep. 2016 Jun 3. doi: 10.3892/or.2016.4853.
    PubMed     Text format     Abstract available


    May 2016
  56. ZHANG YF, Yu Y, Song WZ, Zhang RM, et al
    miR-410-3p suppresses breast cancer progression by targeting Snail.
    Oncol Rep. 2016 May 23. doi: 10.3892/or.2016.4828.
    PubMed     Text format     Abstract available


  57. KARIM S, Merdad A, Schulten HJ, Jayapal M, et al
    Low expression of leptin and its association with breast cancer: A transcriptomic study.
    Oncol Rep. 2016 May 13. doi: 10.3892/or.2016.4806.
    PubMed     Text format     Abstract available


  58. ZHANG X, Lin D, Jiang R, Li H, et al
    Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition.
    Oncol Rep. 2016 May 12. doi: 10.3892/or.2016.4804.
    PubMed     Text format     Abstract available


  59. YU F, Zhao J, Hu Y, Zhou Y, et al
    The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Oncol Rep. 2016 May 10. doi: 10.3892/or.2016.4799.
    PubMed     Text format     Abstract available


  60. JIANG Q, Pan Y, Cheng Y, Li H, et al
    Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-kappaB signaling pathways.
    Oncol Rep. 2016 May 9. doi: 10.3892/or.2016.4798.
    PubMed     Text format     Abstract available


  61. LIU Q, Wang W, Yang X, Zhao D, et al
    MicroRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancer.
    Oncol Rep. 2016 May 6. doi: 10.3892/or.2016.4788.
    PubMed     Text format     Abstract available


  62. ZHAO Y, Jing Z, Li Y, Mao W, et al
    Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis.
    Oncol Rep. 2016 May 5. doi: 10.3892/or.2016.4785.
    PubMed     Text format     Abstract available


  63. SEO HS, Ku JM, Choi HS, Choi YK, et al
    Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells.
    Oncol Rep. 2016 May 5. doi: 10.3892/or.2016.4786.
    PubMed     Text format     Abstract available


  64. INNAJAK S, Mahabusrakum W, Watanapokasin R
    Goniothalamin induces apoptosis associated with autophagy activation through MAPK signaling in SK-BR-3 cells.
    Oncol Rep. 2016;35:2851-8.
    PubMed     Text format     Abstract available


  65. IZDEBSKA M, Grzanka D, Gagat M, Halas-Wisniewska M, et al
    Downregulation of importin-9 protects MCF-7 cells against apoptosis induced by the combination of garlic-derived alliin and paclitaxel.
    Oncol Rep. 2016;35:3084-93.
    PubMed     Text format     Abstract available


    April 2016
  66. JIAO, Zhang XD
    Myricetin suppresses p21-activated kinase 1 in human breast cancer MCF-7 cells through downstream signaling of the beta-catenin pathway.
    Oncol Rep. 2016 Apr 28. doi: 10.3892/or.2016.4777.
    PubMed     Text format     Abstract available


  67. YAN M, Li X, Tong D, Han C, et al
    miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer.
    Oncol Rep. 2016 Apr 25. doi: 10.3892/or.2016.4767.
    PubMed     Text format     Abstract available


  68. CUI L, Song Z, Liang B, Jia L, et al
    Radiation induces autophagic cell death via the p53/DRAM signaling pathway in breast cancer cells.
    Oncol Rep. 2016 Apr 19. doi: 10.3892/or.2016.4752.
    PubMed     Text format     Abstract available


  69. LIU B, Tian Y, Li F, Zhao Z, et al
    Tumor-suppressing roles of miR-214 and miR-218 in breast cancer.
    Oncol Rep. 2016 Apr 15. doi: 10.3892/or.2016.4749.
    PubMed     Text format     Abstract available


  70. ZHANG J, Ma Y, Wang S, Chen F, et al
    Suppression of SOX18 by siRNA inhibits cell growth and invasion of breast cancer cells.
    Oncol Rep. 2016 Apr 15. doi: 10.3892/or.2016.4746.
    PubMed     Text format     Abstract available


  71. JI P, Zhang Y, Wang SJ, Ge HL, et al
    CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs.
    Oncol Rep. 2016 Apr 11. doi: 10.3892/or.2016.4739.
    PubMed     Text format     Abstract available


  72. MEDINA-AGUILAR R, Marchat LA, Arechaga Ocampo E, Gariglio P, et al
    Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
    Oncol Rep. 2016 Apr 4. doi: 10.3892/or.2016.4728.
    PubMed     Text format     Abstract available


  73. DUBE S, Thomas A, Abbott L, Benz P, et al
    Expression of tropomyosin 2 gene isoforms in human breast cancer cell lines.
    Oncol Rep. 2016 Apr 4. doi: 10.3892/or.2016.4732.
    PubMed     Text format     Abstract available


    March 2016
  74. PARK SY, Chae SY, Park JO, Lee KJ, et al
    Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells.
    Oncol Rep. 2016 Mar 29. doi: 10.3892/or.2016.4716.
    PubMed     Text format     Abstract available


  75. CHOY C, Raytis JL, Smith DD, Duenas M, et al
    Inhibition of beta2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative beta-blockade.
    Oncol Rep. 2016 Mar 28. doi: 10.3892/or.2016.4710.
    PubMed     Text format     Abstract available


  76. FAN H, Liang Y, Jiang B, Li X, et al
    Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells.
    Oncol Rep. 2016 Mar 17. doi: 10.3892/or.2016.4682.
    PubMed     Text format     Abstract available


  77. KIM J, Lee J, Jang SY, Kim C, et al
    Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
    Oncol Rep. 2016 Mar 11. doi: 10.3892/or.2016.4675.
    PubMed     Text format     Abstract available


  78. TANG X, Tang J, Liu X, Zeng L, et al
    Downregulation of miR-129-2 by promoter hypermethylation regulates breast cancer cell proliferation and apoptosis.
    Oncol Rep. 2016 Mar 2. doi: 10.3892/or.2016.4647.
    PubMed     Text format     Abstract available


    February 2016
  79. MOROHASHI S, Yoshizawa T, Seino H, Hirai H, et al
    A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy.
    Oncol Rep. 2016 Feb 25. doi: 10.3892/or.2016.4635.
    PubMed     Text format     Abstract available


  80. DING X, Yang Q, Kong X, Haffty BG, et al
    Radiosensitization effect of Huaier on breast cancer cells.
    Oncol Rep. 2016 Feb 23. doi: 10.3892/or.2016.4630.
    PubMed     Text format     Abstract available


  81. ZHOU L, Jiang S, Fu Q, Smith K, et al
    FASN, ErbB2-mediated glycolysis is required for breast cancer cell migration.
    Oncol Rep. 2016 Feb 19. doi: 10.3892/or.2016.4627.
    PubMed     Text format     Abstract available


  82. ANDERGASSEN U, Kolbl AC, Mahner S, Jeschke U, et al
    Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review).
    Oncol Rep. 2016 Feb 2. doi: 10.3892/or.2016.4608.
    PubMed     Text format     Abstract available


  83. CHOI HY, Park N, Na JB, Ko ES, et al
    Direct binding of Copine3 with Jab1 activates downstream ErbB2 signaling and motility in SKBr3 breast cancer cells.
    Oncol Rep. 2016;35:1147-1152.
    PubMed     Text format     Abstract available


  84. YAO J, Xu T, Tian T, Fu X, et al
    Tripartite motif 16 suppresses breast cancer stem cell properties through regulation of Gli-1 degradation via the ubiquitin-proteasome pathway.
    Oncol Rep. 2016;35:1204-1212.
    PubMed     Text format     Abstract available


  85. ZHAO Z, Sun YS, Chen W, Lv LX, et al
    Hispolon inhibits breast cancer cell migration by reversal of epithelial-to-mesenchymal transition via suppressing the ROS/ERK/Slug/E-cadherin pathway.
    Oncol Rep. 2016;35:896-904.
    PubMed     Text format     Abstract available


  86. JIN Y, Zhang W, Wang H, Zhang Z, et al
    EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.
    Oncol Rep. 2016;35:771-778.
    PubMed     Text format     Abstract available


  87. OUYANG W, Zhang S, Yang B, Yang C, et al
    beta-catenin is regulated by USP9x and mediates resistance to TRAIL-induced apoptosis in breast cancer.
    Oncol Rep. 2016;35:717-724.
    PubMed     Text format     Abstract available


    January 2016
  88. LIANG AL, Zhang TT, Zhou N, Wu CY, et al
    miRNA-10b sponge: An anti-breast cancer study in vitro.
    Oncol Rep. 2016 Jan 26. doi: 10.3892/or.2016.4596.
    PubMed     Text format     Abstract available


  89. YANG F, Tang XY, Liu H, Jiang ZW, et al
    Inhibition of mitogen-activated protein kinase signaling pathway sensitizes breast cancer cells to endoplasmic reticulum stress-induced apoptosis.
    Oncol Rep. 2016 Jan 20. doi: 10.3892/or.2016.4580.
    PubMed     Text format     Abstract available


  90. XU M, Jiang D, Shen J, Zheng H, et al
    Distinct characterization of two vinorelbine-resistant breast cancer cell lines developed by different strategies.
    Oncol Rep. 2016 Jan 15. doi: 10.3892/or.2016.4566.
    PubMed     Text format     Abstract available


  91. LI K, Ying M, Feng D, Chen Y, et al
    SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
    Oncol Rep. 2016 Jan 15. doi: 10.3892/or.2016.4564.
    PubMed     Text format     Abstract available


  92. KIM S, Jeon M, Lee JE, Nam SJ, et al
    MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells.
    Oncol Rep. 2016 Jan 13. doi: 10.3892/or.2016.4557.
    PubMed     Text format     Abstract available


  93. LI M, Xing S, Zhang H, Shang S, et al
    A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
    Oncol Rep. 2016 Jan 5. doi: 10.3892/or.2016.4547.
    PubMed     Text format     Abstract available


  94. DI D, Chen L, Wang L, Sun P, et al
    Downregulation of human intercellular adhesion molecule-1 attenuates the metastatic ability in human breast cancer cell lines.
    Oncol Rep. 2016 Jan 5. doi: 10.3892/or.2016.4543.
    PubMed     Text format     Abstract available


    December 2015
  95. HU F, Zhang Y, Li M, Zhao L, et al
    BMP-6 inhibits the metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression.
    Oncol Rep. 2015 Dec 31. doi: 10.3892/or.2015.4540.
    PubMed     Text format     Abstract available


  96. FAN J, Jiang H, Cheng L, Liu R, et al
    The oncolytic herpes simplex virus vector, G47Delta, effectively targets tamoxifen-resistant breast cancer cells.
    Oncol Rep. 2015 Dec 30. doi: 10.3892/or.2015.4539.
    PubMed     Text format     Abstract available


  97. KONG H, Liu X, Yang L, Qi K, et al
    All-trans retinoic acid enhances bystander effect of suicide gene therapy in the treatment of breast cancer.
    Oncol Rep. 2015 Dec 29. doi: 10.3892/or.2015.4535.
    PubMed     Text format     Abstract available


  98. ZHU C, He L, Zhou X, Nie X, et al
    Sulfatase 2 promotes breast cancer progression through regulating some tumor-related factors.
    Oncol Rep. 2015 Dec 28. doi: 10.3892/or.2015.4525.
    PubMed     Text format     Abstract available


  99. YANG J, Yu H, Zhang L, Deng H, et al
    Overexpressed genes associated with hormones in terminal ductal lobular units identified by global transcriptome analysis: An insight into the anatomic origin of breast cancer.
    Oncol Rep. 2015 Dec 28. doi: 10.3892/or.2015.4523.
    PubMed     Text format     Abstract available


  100. YEN MC, Shih YC, Hsu YL, Lin ES, et al
    Isolinderalactone enhances the inhibition of SOCS3 on STAT3 activity by decreasing miR-30c in breast cancer.
    Oncol Rep. 2015 Dec 22. doi: 10.3892/or.2015.4503.
    PubMed     Text format     Abstract available


  101. JIANG Q, He M, Ma MT, Wu HZ, et al
    MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1.
    Oncol Rep. 2015 Dec 21. doi: 10.3892/or.2015.4502.
    PubMed     Text format     Abstract available


    November 2015
  102. ZONG JC, Wang X, Zhou X, Wang C, et al
    Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
    Oncol Rep. 2015 Nov 16. doi: 10.3892/or.2015.4430.
    PubMed     Text format     Abstract available


  103. ZHENG Y, Lv X, Wang X, Wang B, et al
    miR-181b promotes chemoresistance in breast cancer by regulating Bim expression.
    Oncol Rep. 2015 Nov 13. doi: 10.3892/or.2015.4417.
    PubMed     Text format     Abstract available


  104. CHEN CP, Sun ZL, Lu X, Wu WX, et al
    miR-340 suppresses cell migration and invasion by targeting MYO10 in breast cancer.
    Oncol Rep. 2015 Nov 12. doi: 10.3892/or.2015.4411.
    PubMed     Text format     Abstract available


  105. JOO JH, Hong SS, Cho YR, Seo DW, et al
    10-Gingerol inhibits proliferation and invasion of MDA-MB-231 breast cancer cells through suppression of Akt and p38MAPK activity.
    Oncol Rep. 2015 Nov 9. doi: 10.3892/or.2015.4405.
    PubMed     Text format     Abstract available


  106. FU J, Ke X, Tan S, Liu T, et al
    The natural compound codonolactone attenuates TGF-beta1-mediated epithelial-to-mesenchymal transition and motility of breast cancer cells.
    Oncol Rep. 2015 Nov 4. doi: 10.3892/or.2015.4394.
    PubMed     Text format     Abstract available


  107. ZHU Y, Guo M, Zhang L, Xu T, et al
    Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
    Oncol Rep. 2015 Nov 3. doi: 10.3892/or.2015.4391.
    PubMed     Text format     Abstract available


  108. ANANDI VL, Ashiq KA, Nitheesh K, Lahiri M, et al
    Platelet-activating factor promotes motility in breast cancer cells and disrupts non-transformed breast acinar structures.
    Oncol Rep. 2015 Nov 3. doi: 10.3892/or.2015.4387.
    PubMed     Text format     Abstract available


  109. WU J, Zhu Y, Xu C, Xu H, et al
    Adenovirus-mediated p53 and ING4 gene cotransfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
    Oncol Rep. 2015 Nov 3. doi: 10.3892/or.2015.4385.
    PubMed     Text format     Abstract available


    October 2015
  110. HAN M, Wang F, Gu Y, Pei X, et al
    MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-beta pathways.
    Oncol Rep. 2015 Oct 29. doi: 10.3892/or.2015.4360.
    PubMed     Text format     Abstract available


    June 2015
  111. ZHANG Y, Luo W, Wang Y, Chen J, et al
    Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells.
    Oncol Rep. 2015;33:2695-702.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: